RxDoctor Payments Data

Kendra Back

Family · Newland, NCNPI 1437408093

Payments from drug & device makers

$3,284in general payments, 2019–2025

Across 188 payments — averaging $17.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$869
  • Novo Nordisk$436
  • Lilly USA, LLC$351
  • Pfizer$349
  • GSK$200
  • Bayer$176
  • plus $903 from 19 others

What the payments were for

  • Food & beverage$3,284100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,284 in reported general payments places this provider in the 90th percentile of 4,522 family providers in North Carolina.

See all family providers in North Carolina

Medicare billing

Part B allowed, 2024
$74,579
Medicare patients
536
Services billed
1,474

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Lagevrio (Eua)Molnupiravir27$8,896
PaxlovidNirmatrelvir/Ritonavir25$2,884
Cefdinir123$1,561
Azithromycin241$923
Doxycycline Monohydrate63$896
Fluticasone Propionate62$853
Neomycin-Polymyxin-HcNeomycin/Polymyxin B/Hydrocort14$668
Methylprednisolone145$591
Albuterol Sulfate HfaAlbuterol Sulfate26$523
Cephalexin77$514
Azelastine Hcl28$511
Amoxicillin149$473
MoxifloxacinMoxifloxacin Hcl21$458
ValacyclovirValacyclovir Hcl16$447
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst42$412

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckLagevrio (Eua)$47$8,89627 claims
PfizerPaxlovid$349$2,88425 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,522 family providers in North Carolina.

Other family in Newland

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →